# Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol

> **NCT00531050** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 27 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol
- **DRUG:** Placebo
- **DRUG:** Salmeterol

## Key facts

- **NCT ID:** NCT00531050
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531050, "Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00531050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*